Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC :

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.

Related Keywords

Utah , United States , Texas , San Antonio , France , University Of Texas , Paris , France General , American , Bristol Myers Squibb , Neil Newman , Thierry Andre , Mark Lewis , Drug Administration , University Of Texas Health Science Center , Sorbonne University , Clinical Oncology Gastrointestinal Cancers , Texas Health Science Center , Intermountain Healthcare , Medscape Medical News , Colorectal Cancer , Colorectal Cancer Crc , Chemotherapy , Biologic Therapy , Iologics , Metastatic Colorectal Cancer , Metastatic Crc , Crc , Etastatic Colorectal Cancer Mcrc , Microsatellite Instability High , Micro Satellite Instability High , Msi H , Immunotherapy , Microsatellite Instability , Si , Breast Cancer , Alignant Breast Neoplasm , Breast Carcinoma ,